Trainet: Diabetes Type 1 Prevention

培训班:1 型糖尿病预防

基本信息

  • 批准号:
    8076277
  • 负责人:
  • 金额:
    $ 61.28万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-09-30 至 2014-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Long-term objective: To find intervention therapies that can delay, prevent or reverse the development of type 1 diabetes (T1D). Specific Aims: 1) BHT-3021 Proinsulin DNA vaccine treatment of recent onset type 1 diabetes subjects Research Design: Preliminary data in animals has shown that using a similar proinsulin DNA vaccine can reverse diabetes in hyperglycemic mice. Pre-clinical studies in mice and non-human primates have found no toxicity for this therapy and have suggested a dosing scheme which could be effective in human subjects with T1D. An ongoing phase 1 study has confirmed the safety of this treatment and has suggested potential efficacy in type 1 diabetes subjects >3 months from diagnosis who still have C-peptide present. The current trial will test 2 doses, 1 and 3 mg, given weekly for 12 doses in a new onset patient population. It will use established measures to determine the effect on C-peptide, HbA1c, total insulin use and other safety parameters. Mechanistic studies to look at effects on insulin and other autoantibodies, T cells and other immune effects will be performed to better understand the potential mechanism of effect. 2) Renewal of TrialNet Center Research Design: The Barbara Davis Center has been at the forefront of defining populations at risk for T1D and other autoimmune diseases and in recruiting patients for the TrialNet Natural History study as well as other TrialNet studies. The BDC TrialNet Center has helped to develop two of the first protocols, TN02 (MMF and DZB in new onset T1D), and TN06 (Nutritional Intervention to Prevent [NIP] Diabetes). Our proposal for renewal outlines our past efforts, current approaches and future goals to not only maintain our current level of productivity, but to increase productivity over the next funding cycle. PUBLIC HEALTH RELEVANCE: The purpose of this research is to investigate methods to prevent diabetes and/or to prolong insulin production in people who have been recently diagnosed with type 1 diabetes.
描述(由申请人提供):长期目标:寻找可以延缓、预防或逆转1型糖尿病(T1D)发展的干预疗法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

PETER A GOTTLIEB其他文献

PETER A GOTTLIEB的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('PETER A GOTTLIEB', 18)}}的其他基金

Trainet: Diabetes Type 1 Prevention
培训班:1 型糖尿病预防
  • 批准号:
    7790104
  • 财政年份:
    2009
  • 资助金额:
    $ 61.28万
  • 项目类别:
TrialNet: Diabetes Type 1 Prevention
TrialNet:1 型糖尿病预防
  • 批准号:
    9268733
  • 财政年份:
    2009
  • 资助金额:
    $ 61.28万
  • 项目类别:
TrialNet: Diabetes Type 1 Prevention
TrialNet:1 型糖尿病预防
  • 批准号:
    8919876
  • 财政年份:
    2009
  • 资助金额:
    $ 61.28万
  • 项目类别:
TrialNet: Diabetes Type 1 Prevention
TrialNet:1 型糖尿病预防
  • 批准号:
    9066681
  • 财政年份:
    2009
  • 资助金额:
    $ 61.28万
  • 项目类别:
Trainet: Diabetes Type 1 Prevention
培训班:1 型糖尿病预防
  • 批准号:
    8831770
  • 财政年份:
    2009
  • 资助金额:
    $ 61.28万
  • 项目类别:
Trainet: Diabetes Type 1 Prevention
培训班:1 型糖尿病预防
  • 批准号:
    8490602
  • 财政年份:
    2009
  • 资助金额:
    $ 61.28万
  • 项目类别:
Trainet: Diabetes Type 1 Prevention
培训班:1 型糖尿病预防
  • 批准号:
    8284422
  • 财政年份:
    2009
  • 资助金额:
    $ 61.28万
  • 项目类别:
TrialNet: Diabetes Type 1 Prevention
TrialNet:1 型糖尿病预防
  • 批准号:
    8776002
  • 财政年份:
    2009
  • 资助金额:
    $ 61.28万
  • 项目类别:
Trainet: Diabetes Type 1 Prevention
培训班:1 型糖尿病预防
  • 批准号:
    7939573
  • 财政年份:
    2009
  • 资助金额:
    $ 61.28万
  • 项目类别:
IMMUNOTHERAPY TRIAL FOR NEW ONSET TYPE 1 DIABETES
新发 1 型糖尿病的免疫治疗试验
  • 批准号:
    7719503
  • 财政年份:
    2008
  • 资助金额:
    $ 61.28万
  • 项目类别:

相似海外基金

Defining the cellular origin of pathogenic autoantibodies
定义致病性自身抗体的细胞起源
  • 批准号:
    EP/Y031091/1
  • 财政年份:
    2024
  • 资助金额:
    $ 61.28万
  • 项目类别:
    Fellowship
Do autoantibodies to aberrantly glycosylated MUC1 drive extra-articular rheumatoid arthritis, and can GSK assets prevent driver antigen formation?
针对异常糖基化 MUC1 的自身抗体是否会导致关节外类风湿性关节炎,GSK 资产能否阻止驱动抗原形成?
  • 批准号:
    MR/Y022947/1
  • 财政年份:
    2024
  • 资助金额:
    $ 61.28万
  • 项目类别:
    Research Grant
Autoantibodies and antibody-secreting cells in neurological autoimmune diseases: from biology to therapy
神经性自身免疫性疾病中的自身抗体和抗体分泌细胞:从生物学到治疗
  • 批准号:
    479128
  • 财政年份:
    2023
  • 资助金额:
    $ 61.28万
  • 项目类别:
    Operating Grants
Autoantibodies to tumor-derived neoepitopes as biomarkers and immunoPET agents for the early detection of small cell lung cancer
肿瘤衍生新表位的自身抗体作为生物标志物和免疫 PET 试剂用于小细胞肺癌的早期检测
  • 批准号:
    10715807
  • 财政年份:
    2023
  • 资助金额:
    $ 61.28万
  • 项目类别:
Role of pharmacological activity of autoantibodies in ME/CFS
自身抗体药理活性在 ME/CFS 中的作用
  • 批准号:
    MR/Y003667/1
  • 财政年份:
    2023
  • 资助金额:
    $ 61.28万
  • 项目类别:
    Research Grant
Pathological Mechanisms of Immune-Mediated Cerebellar Ataxia with Associated Sez6L2 Autoantibodies
免疫介导的小脑共济失调与相关 Sez6L2 自身抗体的病理机制
  • 批准号:
    10740682
  • 财政年份:
    2023
  • 资助金额:
    $ 61.28万
  • 项目类别:
Sjogren's Syndrome Pathogenic Autoantibodies
干燥综合征致病性自身抗体
  • 批准号:
    10854472
  • 财政年份:
    2023
  • 资助金额:
    $ 61.28万
  • 项目类别:
Pathogenesis of idiopathic nephrotic syndrome: defining the role of B cells and autoantibodies reactive to podocyte proteins
特发性肾病综合征的发病机制:定义 B 细胞和足细胞蛋白反应性自身抗体的作用
  • 批准号:
    487849
  • 财政年份:
    2023
  • 资助金额:
    $ 61.28万
  • 项目类别:
    Operating Grants
Analysis of pathogenesis associated with mutation of complement associated gene and autoantibodies in development/progression of C3 nephropathy.
补体相关基因突变和自身抗体在C3肾病发生/进展中的发病机制分析。
  • 批准号:
    22K08309
  • 财政年份:
    2022
  • 资助金额:
    $ 61.28万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Depleting autoantibodies for the treatment of autoimmunity
消耗自身抗体来治疗自身免疫
  • 批准号:
    10481071
  • 财政年份:
    2022
  • 资助金额:
    $ 61.28万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了